These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 38724041

  • 1. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.
    Paller AS, Guide SV, Ayala D, Gonzalez ME, Lucky AW, Bagci IS, Marinkovich MP.
    J Dermatolog Treat; 2024 Dec; 35(1):2350232. PubMed ID: 38724041
    [Abstract] [Full Text] [Related]

  • 2. Beremagene Geperpavec: First Approval.
    Dhillon S.
    Drugs; 2023 Aug; 83(12):1131-1135. PubMed ID: 37432558
    [Abstract] [Full Text] [Related]

  • 3. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
    Guide SV, Gonzalez ME, Bağcı IS, Agostini B, Chen H, Feeney G, Steimer M, Kapadia B, Sridhar K, Quesada Sanchez L, Gonzalez F, Van Ligten M, Parry TJ, Chitra S, Kammerman LA, Krishnan S, Marinkovich MP.
    N Engl J Med; 2022 Dec 15; 387(24):2211-2219. PubMed ID: 36516090
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A.
    J Invest Dermatol; 2021 Apr 15; 141(4):883-893.e6. PubMed ID: 32946877
    [Abstract] [Full Text] [Related]

  • 13. Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.
    Ito K, Sawamura D, Goto M, Nakamura H, Nishie W, Sakai K, Natsuga K, Shinkuma S, Shibaki A, Uitto J, Denton CP, Nakajima O, Akiyama M, Shimizu H.
    Am J Pathol; 2009 Dec 15; 175(6):2508-17. PubMed ID: 19893033
    [Abstract] [Full Text] [Related]

  • 14. Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa.
    Khan A, Riaz R, Ashraf S, Akilimali A.
    Ann Med Surg (Lond); 2023 Dec 15; 85(12):6298-6301. PubMed ID: 38098548
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
    Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon PM, Mazurek C, Woodley DT.
    Nat Genet; 2002 Dec 15; 32(4):670-5. PubMed ID: 12426566
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
    Dang N, Murrell DF.
    Exp Dermatol; 2008 Jul 15; 17(7):553-68. PubMed ID: 18558993
    [Abstract] [Full Text] [Related]

  • 20. Gene therapy for recessive dystrophic epidermolysis bullosa.
    Titeux M, Pendaries V, Hovnanian A.
    Dermatol Clin; 2010 Apr 15; 28(2):361-6, xii. PubMed ID: 20447504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.